Beyond SS and SLE, anti-TRIM21 antibodies have also been identified in patients with primary biliary cirrhosis, idiopathic inflammatory myopathies (mainly polymyositis and dermatomyositis), and infants with congenital heart block (CHB) associated with maternal autoantibody transfer (6–9). This evidence concerns the gene TRIM21 and synovial sarcoma.